Physician profile
Harry Croft
NPI 1790830263
$18,719.96
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $27.60 · 2021: $2,042 · 2022: $75.77 · 2023: $17.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $11,396.39 | 2019-2022 | |
| Alkermes, INC. | $5,100.00 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,045.68 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $77.89 | 2019 | |
| Lundbeck LLC | $72.40 | 2021-2023 | |
| Sage Therapeutics, LLC | $27.60 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Croft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.